SGLT-2 Therapy Center

Various T2 factors create need for multiple treatment options.

To maintain the benefits while minimizing risk, consider patient risk factors when prescribing, and monitor for DKA and UTI.

New study generates lively discussion among experts at EASD on how to consider the results in prescribing, exploration of possible mechanism and potential class effect.

In this week's Homerun Slides, the effect of dapagliflozin on endogenous glucose production, plasma insulin and glucagon concentration.

Diabetes experts conclude diabetes treatment should continue with no changes in current recommendations.

In this week’s Homerun Slides, we look at SGLT2 Inhibition as a novel treatment strategy for type 2 diabetes.

Findings suggest significant reduction in the risk of CV death and all-cause mortality for T2DM patients with a history of CVD.

Dr. Christophe Arbet-Engels talks about how the empagliflozin study results were very positive in terms of lowering A1c, and goes over the basics of how the new class of SGLT-2 inhibitor drugs work, removing excess glucose, inducing some weight loss, and that there is potential for a decrease in blood pressure …

Christophe Arbet-Engels, MD, PhD, MBA, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc., gives us a brief introduction to himself. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels, discusses some of the study results on empagliflozin in which more than 14,000 patients were involved in several different study configurations including monotherapy, empagliflozin as an add-on, and patients with renal impairment.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer …